Unravelling the Smokers' Paradox: Cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors

Thrombosis and Haemostasis

Volumn 111, Issue 6, 2014, Pages 1187-1190

  Gurbel, Paul A ^a   Baker, Brian A ^b   Bailey, William L ^b   Bliden, Kevin P ^a   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 13A; CLOPIDOGREL; CYTOCHROME P450 1A2; FIBRINOGEN; GLYCOPROTEIN IIB; INTERLEUKIN 6; PADGEM PROTEIN; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR INHIBITOR; TICAGRELOR; UNCLASSIFIED DRUG; ADENOSINE; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DRUG EFFICACY; HEART INFARCTION; HUMAN; LETTER; PHARMACODYNAMICS; PRIORITY JOURNAL; SMOKING; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; ORAL DRUG ADMINISTRATION; RISK REDUCTION; TREATMENT OUTCOME;

ADENOSINE; ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK REDUCTION BEHAVIOR; SMOKING; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84901952563     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-08-0642     Document Type: Letter

References (42)

1. Åberg A, Bergstrand R, Johansson S, et al. Cessation of smoking after myocardial infarction: effects on mortality after 10 years. Br Heart J 1983; 49: 416-422.
2. Centers for Disease Control and Prevention (US); National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. 6, Cardiovascular Diseases. Available from: http://www. ncbi.nlm.nih.gov/books/NBK53012/. Accessed June 11, 2013.
3. Csordas A, Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. Nat Rev Cardiol 2013; 10: 219-230.
4. Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler Thromb Vasc Biol 2013; 33: 1460-1467.
5. Newby DE, Wright RA, Labinjoh C, et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking:a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999; 99: 1411-1415.
6. Kelly TL, Gilpin E, Ahnve S, et al. Smoking status at the time of acute myocardial infarction and subsequent prognosis. Am Heart J 1985; 110: 535-541.
7. Sparrow D, Dawber TR. The influence of cigarette smoking on prognosis after a first myocardial infarction. A report from the Framingham study. J Chronic Dis 1978; 31: 425-432.
8. Gomez MA, Karagounis LA, Allen A, et al. Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. TEAM-2 investigators. Second multicenter thrombolytic trials of eminase in acute myocardial infarction. Am J Cardiol 1993; 72: 373-378.
9. Barbash GI, Reiner J, White HD, et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global utilization of streptokinase and tissue-plasminogen activator for occluded coronary arteries. J Am Coll Cardiol 1995; 26: 1222-1229.
10. Addad F, Dridi Z, Jemmali M, et al. "Smoker's paradox" and reperfusion's strategy in acute myocardial infarction. Ann Cardiol Angiol 2010; 59: 183-189.
11. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I investigators. Circulation 1995; 91: 1659-1668.
12. Andrikopoulos GK, Richter DJ, Dilaveris PE, et al. In-hospital mortality of habitual cigarette smokers after acute myocardial infarction; the "smoker's paradox" in a countrywide study. Eur Heart J 2001; 22: 776-784.
13. Aune E, Roislien J, Mathisen M, et al. The "smoker's paradox" in patients with acute coronary syndrome: a systematic review. BMC Med 2011; 9: 97.
14. Smith EE, Shobha N, Dai D, et al. Risk score for inhospital ischaemic stroke mortality derived and validated within the get with the guidelines-stroke program. Circulation 2010; 122: 1496-1504.
15. van Domburg RT, Meeter K, van Berkel DF, et al. Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study. J Am Coll Cardiol 2000; 36: 878-883.
16. Ali SF, Smith EE, Bhatt DL, et al. Paradoxical association of smoking with in-hospital mortality among patients admitted with acute ischaemic stroke. J Am Heart Assoc 2013; 2: e000171.
17. Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. J Am Med Assoc 2012; 307: 2495-2496.
18. Bliden KP, Baker BA, Nolin TD, et al. Thienopyridine efficacy and cigarette smoking status. Am Heart J 2013; 165: 693-703.
19. Gurbel PA, Bliden KP, Logan DK, et al. The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel: The PARADOX Study. J Am Coll Cardiol 2013; 62: 505-512.
20. Zhao ZG, Chen M, Peng Y, Chai H, et al. The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. Heart 2013; Epub ahead of print.
21. Huber K, Schrör K. High on-treatment platelet reactivity--why should we be concerned? Thromb Haemost 2013; 109: 789-791.
22. Dahlen JR, Price MJ, Parise H, et al. Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. Thromb Haemost 2013; 109: 808-816.
23. Cattaneo M. High on-treatment platelet reactivity--definition and measurement. Thromb Haemost 2013; 109: 792-798.
24. Park KW, Park JJ, Jeon KH, et al. Enhanced clopidogrel responsiveness in smokers: smokers' paradox is dependent on cytochrome P450 CYP1A2 status. Arterioscler Thromb Vasc Biol 2011; 31: 665-671.
25. Shanker G, Kontos JL, Eckman DM, et al. Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis 2006; 22: 213-220.
26. Hochholzer W, Trenk D, Mega JL, et al. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J 2011; 162: 518-526. e5.
27. Cornel JH, Becker RC, Goodman SG, et al. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2012; 164: 334-342. e1.
28. Cornel JH, Ohman EM, Neely B, et al. Impact of smoking status on clinical outcomes with prasugrel versus clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. J Am Coll Cardiol 2013; 61 (Suppl. A): A39.
29. Gurbel PA, Erlinge D, Ohman, EM, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization. The TRILOGY ACS platelet function substudy. J Am Med Assoc 2012; 308: 1785-1794.
30. Rubenstein D, Jesty J, Bluestein D. Differences between mainstream and sidestream cigarette smoke extracts and nicotine in the activation of platelets under static and flow conditions. Circulation 2004; 109: 78-83.
31. Blache D. Involvement of hydrogen and lipid peroxides in acute tobacco smoking-induced platelet hyperactivity. Am J Physiol 1995; 268: H679-685.
32. Lupia E, Bosco O, Goffi A, et al. Thrombopoietin contributes to enhanced platelet activation in cigarette smokers. Atherosclerosis 2010; 210: 314-319.
33. Assinger A, Schmid W, Volf I. Decreased VASP phosphorylation in platelets of male and female smokers of young age. Platelets 2010; 21: 596-603.
34. Della Corte A, Tamburrelli C, Crescente M, et al. Platelet proteome in healthy volunteers who smoke. Platelets 2012; 23: 91-105.
35. Tuut M, Hense HW. Smoking, other risk factors and fibrinogen levels. evidence of effect modification. Ann Epidemiol 2001; 11: 232-238.
36. Sinha S, Luben RN, Welch A, et al. Fibrinogen and cigarette smoking in men and women in the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population. Eur J Cardiovasc Prev Rehabil 2005; 12: 144-150.
37. Balleisen L, Bailey J, Epping PH, et al. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill using, and menopause. Thromb Haemost 1985; 54: 475-479.
38. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113: 1006-1010.
39. Frohlich M, Sund M, Lowel H, et al. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003; 24: 1365-1372.
40. Mannucci PM. Recent progress in the pathophysiology of fibrinogen. Eur Heart J 1995; 16 (Suppl A): 25-30.
41. Tappia PS, Troughton KL, Langley-Evans SC, et al. Cigarette smoking influences cytokine production and antioxidant defences. Clin Sci 1995; 88: 485-489.
42. Barua RS, Sy F, Srikanth S, et al. Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation. Arterioscler Thromb Vasc Biol 2010; 30: 75-79.